Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study

Data on adjuvant chemotherapy (CT) benefit in ER + HER2‒ early-stage breast cancer (EBC) patients with Recurrence Score (RS) 26-30 are limited. This real-world study evaluated the relationships between the RS, adjuvant treatments, and outcomes in 534 RS 26-30 patients tested through Clalit Health Se...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotem, Ofer, Peretz, Idit, Leviov, Michelle, Kuchuk, Iryna, Itay, Amit, Tokar, Margarita, Paluch-Shimon, Shani, Maimon, Ofra, Yerushalmi, Rinat, Drumea, Karen, Evron, Ella, Sonnenblick, Amir, Gal-Yam, Einav, Goldvaser, Hadar, Samih, Yosef, Merose, Rotem, Bareket-Samish, Avital, Soussan-Gutman, Lior, Stemmer, Salomon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238504/
https://www.ncbi.nlm.nih.gov/pubmed/37268607
http://dx.doi.org/10.1038/s41523-023-00549-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238504/
https://www.ncbi.nlm.nih.gov/pubmed/37268607
http://dx.doi.org/10.1038/s41523-023-00549-8

Ejemplares similares